| 2024 | | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | 이현우 |
| 2022 | | Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma | 고영화, 이현우, 한재호, 함석진 |
| 2020 | | Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma | 이현우 |
| 2024 | | Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study | 이현우 |
| 2022 | | The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study | 강석윤, 김세혁, 노오규, 노태훈, 신승수, 안미선, 오영택, 이현우, 최용원, 최진혁 |
| 2019 | | The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: A retrospective nationwide population-based cohort study | 강석윤, 안미선, 이현우 |
| 2023 | | Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study | 강석윤, 권민석, 김태환, 손상용, 신승수, 안미선, 이현우, 최용원, 최진혁, 한상욱, 허훈 |
| 2022 | | Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22 | 이현우 |
| 2021 | | Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data | 강석윤, 김태환, 신승수, 안미선, 이현우, 조헌도, 최용원, 최진혁 |
| 2021 | | Treatment Outcomes of 9,994 Patients With Extensive-Disease Small-Cell Lung Cancer From a Retrospective Nationwide Population-Based Cohort in the Korean HIRA Database | 이현우 |
| 2021 | | Tumor nonimmune-microenvironment-related gene expression signature predicts brain metastasis in lung adenocarcinoma patients after surgery: A machine learning approach using gene expression profiling | 고영화, 이현우, 한재호, 함석진 |
